LTR Pharma (ASX:LTP) has entered a collaborative development agreement with Strategic Drug Solutions to co-develop OROFLOW, a novel intranasal spray targeting Oesophageal Motility Disorders (OMD).
OMD are a group of conditions that cause impaired swallowing and impact quality of life for millions worldwide.
LTR said the agreement builds on its work and patent rights for SPONTAN and ROXUS. The company said it would now develop OROFLOW for OMD indications using its proprietary delivery platform and commercialisation capabilities.
It said the program will commence towards proof-of-concept testing over the coming months and is targeted to provide prompt relief from discomfort and swallowing difficulties. OMD are a group of conditions characterised by abnormal contraction or relaxation of the oesophagus, leading to impaired swallowing and related symptoms. Patients with OMD often struggle with swallowing both solids and liquids, and experience regurgitation, chest pain, and sometimes weight loss. Current treatments for OMD include invasive procedures such as pneumatic dilation, surgery, or botulinum toxin injections.
LTR Pharma executive chairman, Lee Rodne, said, "OROFLOW represents an exciting expansion of our nasal spray platform. For patients with swallowing difficulties, oral medications present obvious challenges for patients. Our nasal spray technology is designed to offer a patient-friendly solution that avoids the need to swallow medications, have surgery or undergo other problematic treatments while providing rapid symptom relief.
"The global prevalence of Oesophageal Motility Disorders has been increasing. We believe OROFLOW represents an important innovation that can significantly improve the quality of life for these patients. By addressing this specialised medical need with our proven nasal spray technology, we're pursuing a meaningful opportunity that aligns patient outcomes with long-term value creation."